NanoViricides says Phase IIa Ebola trial of NV — 387 oral gummies progresses well
NanoViricides flagged steady progress in its Phase IIA trial of NV-387 oral gummies for Bundibugyo Ebola in the DRC. No results have been presented yet; a safety and tolerability update is expected once Phase IIA ends and investigators complete a report. The study aims to identify a workable dosing regimen in very ill